Actovegin 40 mg/ml, 10 ml. №5 ampoules
Actovegin is produced on the basis of an extract from blood serum of calves that have not reached the age of one year and includes exclusively physiological components characterized by high bioactivity — low molecular weight organic compounds: amino acids, oligopeptides, nucleosides and electrolytes. Actovegin therapy significantly increases the energy reserves of cells and their resistance to hypoxia due to the normalization of oxygen consumption and glucose.
The use of Actovegin increases the synthesis of Adenazine Triphosphates - the main energy cell battery. Under conditions of intracellular oxygen deficiency, cells provide their own energy needs due to the prevalence of anaerobic enzymatic non-hydrolytic glucose cleavage. The prevalence of anaerobic energy reproduction is the main reason of the development of hypoxic and ischemic damage to the cells of organs and tissues, and perhaps gives an advantage to tumor cells that do not have access to oxygen through blood vessels. The active fraction of the drug increases the transport of glucose up to five times, depending on the size of the dose. The secondary positive effect is improved blood supply to the organs and tissues. If tissue hypoxia is caused by the deterioration of microcirculation, the use of Actovegin can lead to the repair of the capillary network due to the formation of new blood vessels.
Recommendations for use of Actovegin in sports:
Solution for injection has a slightly yellowish tint. The color intensity may vary from one batch to another, depending on the characteristics of the raw materials used, but this does not adversely affect the activity of the drug or its tolerance.